Global Research at UCSF
contact info
  • trending topics
    • Partners Abroad
    • UCSF Affiliated Organizations
  • events
  • Visiting Scholars
  • Interest Groups
    • Alcohol and HIV Interest
    • Child Mental Health
    • Global Health Economics
    • Global Hospitalists
    • Global Maternal & Newborn
    • Global Nursing
    • Global Oncology
    • Global Oral Health
    • Global Pediatrics Interest
    • Global Surgery
    • Global Vision
    • India Interest Group >
      • India/Southeast Asia
    • Infectious Disease Implementation Science
    • Diagnostics
    • Disaster Response
    • Refugee Health
    • Malaria Interest
    • Young Investigators in International Research
  • Newsletter

Diane Havlir

3/3/2014

0 Comments

 
Picture
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Use of antiretroviral treatment for HIV-1 infection has decreased AIDS-related morbidity and mortality and prevents sexual transmission of HIV-1. However, the best time to initiate antiretroviral treatment to reduce progression of HIV-1 infection or non-AIDS clinical events is unknown. We reported previously that early antiretroviral treatment reduced HIV-1 transmission by 96%. We aimed to compare the effects of early and delayed initiation of antiretroviral treatment on clinical outcomes. The HPTN 052 trial is a randomised controlled trial done at 13 sites in nine countries. We enrolled HIV-1-serodiscordant couples to the study and randomly allocated them to either early or delayed antiretroviral treatment by use of permuted block randomisation, stratified by site. Random assignment was unblinded. The HIV-1-infected member of every couple initiated antiretroviral treatment either on entry into the study (early treatment group) or after a decline in CD4 count or with onset of an AIDS-related illness (delayed treatment group). Primary events were AIDS clinical events (WHO stage 4 HIV-1 disease, tuberculosis, and severe bacterial infections) and the following serious medical conditions unrelated to AIDS: serious cardiovascular or vascular disease, serious liver disease, end-stage renal disease, new-onset diabetes mellitus, and non-AIDS malignant disease. Analysis was by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT00074581.

0 Comments



Leave a Reply.

    Author

    GlobalResearch at UCSF presents the broad scope of health research that is being conducted by UCSF researchers worldwide

    Archives

    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013

    Categories

    All
    HIV

    RSS Feed

UCSF Global Projects worldwide

Picture
Learn about UCSF Research across the globe.

UCSF Global Health Sciences (GHS)

Picture
UCSF Global Health Sciences
Our mothership.

Picture

Travel Health & Safety links

Picture

UCSF Global HUB

Picture
Compliance & logistics for global research